Filing Details
- Accession Number:
- 0001102598-25-000037
- Form Type:
- 13G Filing
- Publication Date:
- 2025-02-13 19:00:00
- Filed By:
- AMUNDI
- Company:
- Sanofi Aventis (NYSE:SNY)
- Filing Date:
- 2025-02-14
- SEC Url:
- 13G Filing
Ownership Summary
Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.
Name | Beneficially Owned Number of Shares | Beneficially Owned Number of Aggregate Shares | Percent of Class |
---|---|---|---|
AMUNDI | 0 | 64,334,393 | 5.1% |
Amundi Asset Management US, Inc. | 0 | 64,334,393 | 5.1% |
Filing
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 |
SCHEDULE 13G
|
UNDER THE SECURITIES EXCHANGE ACT OF 1934
|
(Amendment No. 6)
|
Sanofi (Name of Issuer) |
Common Stock and American Depositary Receipts (Title of Class of Securities) |
FR0000120578 (CUSIP Number) |
12/31/2024 (Date of Event Which Requires Filing of this Statement) |
Check the appropriate box to designate the rule pursuant to which this Schedule is filed: |
![]() |
![]() |
![]() |
SCHEDULE 13G
|
CUSIP No. | FR0000120578 |
1 | Names of Reporting Persons
AMUNDI | ||||||||
2 | Check the appropriate box if a member of a Group (see instructions)
![]() ![]() | ||||||||
3 | Sec Use Only | ||||||||
4 | Citizenship or Place of Organization
FRANCE
| ||||||||
Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
9 | Aggregate Amount Beneficially Owned by Each Reporting Person
64,334,393.00 | ||||||||
10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
![]() | ||||||||
11 | Percent of class represented by amount in row (9)
5.1 % | ||||||||
12 | Type of Reporting Person (See Instructions)
HC |
Comment for Type of Reporting Person: Of this number, Amundi does not have the voting rights on 25,271,220 shares which are held through a FCPE (Fonds Commun de Placement d Entreprise, an investment vehicle established under French law), solely dedicated to Sanofi groups employees shareholding. Employees of Sanofi are granted the right to participate in stock purchase plans in which the shares acquired are exclusively held in this FCPE, created at the request of Sanofi. The voting rights associated to these shares are exercised by the supervisory Board of the FCPE, where representatives of the employees have the majority (if any the remaining seats of the supervisory board are designated by Sanofi), and not by Amundi.
SCHEDULE 13G
|
CUSIP No. | FR0000120578 |
1 | Names of Reporting Persons
Amundi Asset Management US, Inc. | ||||||||
2 | Check the appropriate box if a member of a Group (see instructions)
![]() ![]() | ||||||||
3 | Sec Use Only | ||||||||
4 | Citizenship or Place of Organization
FRANCE
| ||||||||
Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
9 | Aggregate Amount Beneficially Owned by Each Reporting Person
64,334,393.00 | ||||||||
10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
![]() | ||||||||
11 | Percent of class represented by amount in row (9)
5.1 % | ||||||||
12 | Type of Reporting Person (See Instructions)
FI |
Comment for Type of Reporting Person: Of this number, Amundi does not have the voting rights on 25,271,220 shares which are held through a FCPE (Fonds Commun de Placement d Entreprise, an investment vehicle established under French law), solely dedicated to Sanofi groups employees shareholding. Employees of Sanofi are granted the right to participate in stock purchase plans in which the shares acquired are exclusively held in this FCPE, created at the request of Sanofi. The voting rights associated to these shares are exercised by the supervisory Board of the FCPE, where representatives of the employees have the majority (if any the remaining seats of the supervisory board are designated by Sanofi), and not by Amundi.
SCHEDULE 13G
|
Item 1. | |
(a) | Name of issuer:
Sanofi |
(b) | Address of issuer's principal executive offices:
46 AVENUE LA GRANDE ARMEE, Paris, France, 75017 |
Item 2. | |
(a) | Name of person filing:
Amundi
Amundi Asset Management |
(b) | Address or principal business office or, if none, residence:
Amundi
91-93 boulevard Pasteur
75015 Paris, France
Amundi Asset Management
90 boulevard Pasteur
75015 Paris, France |
(c) | Citizenship:
Both Amundi and Amundi Asset Management are organized under the laws of the Republic of France. |
(d) | Title of class of securities:
Common Stock and American Depositary Receipts |
(e) | CUSIP No.:
FR0000120578 |
Item 4. | Ownership |
(a) | Amount beneficially owned:
See Item 9 of each cover page. |
(b) | Percent of class:
See Item 11 of each cover page. |
(c) | Number of shares as to which the person has:
|
(i) Sole power to vote or to direct the vote:
See Item 5 of each cover page. | |
(ii) Shared power to vote or to direct the vote:
See Item 6 of each cover page. | |
(iii) Sole power to dispose or to direct the disposition of:
See Item 7 of each cover page. | |
(iv) Shared power to dispose or to direct the disposition of:
See Item 8 of each cover page. | |
Item 5. | Ownership of 5 Percent or Less of a Class. |
Item 6. | Ownership of more than 5 Percent on Behalf of Another Person. |
Not Applicable
| |
Item 7. | Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person. |
If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
See Attached Appendix A. | |
Item 8. | Identification and Classification of Members of the Group. |
Not Applicable
| |
Item 9. | Notice of Dissolution of Group. |
Not Applicable
|
Item 10. | Certifications: |
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. |
SIGNATURE | |
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
|
|
|
|
Comments accompanying signature: Lisa M. Jones; President and Chief Executive Officer; Head of the Americas Amundi US, Inc.; By Power of Attorney